Clinical Trials Directory

Trials / Completed

CompletedNCT00946725

To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg

A Comparative Bioavailability Study of Atenolol Tablets, 100 mg

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
28 (actual)
Sponsor
Sandoz · Industry
Sex
Male
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

To demonstrate the relative bioavailability of atenolol tablets, 100 mg.

Conditions

Interventions

TypeNameDescription
DRUGAtenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)
DRUGAtenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)

Timeline

Start date
2000-11-01
Primary completion
2000-11-01
Completion
2000-11-01
First posted
2009-07-27
Last updated
2017-03-28

Source: ClinicalTrials.gov record NCT00946725. Inclusion in this directory is not an endorsement.

To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg (NCT00946725) · Clinical Trials Directory